News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 512 KB

  • Epigenomics’ DNA methylation biomarkers demonstrate high sensitivity compared to commonly used protein biomarkers
  • Being developed as a blood-based test for early lung cancer detection and treatment monitoring
  • Initial results presented at the Association for Molecular Pathology (AMP) 2015 Annual Meeting

 
Berlin (Germany) and Germantown, MD (U.S.A.), November 9, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, presented promising data from a study using a proprietary panel of blood-based DNA methylation biomarkers for the detection of lung cancer. The results were presented at Epigenomics’ Corporate Workshop and in a poster session at the Association for Molecular Pathology (AMP) 2015 Annual Meeting in Austin, Texas.

“We are very excited about the potential for a new blood-based test to enable the detection and subsequent timely treatment of lung cancer”, said Dr. Uwe Staub, COO of Epigenomics AG. “Given the excellent sensitivity demonstrated in comparison with commonly used biomarkers, this test may also show significant clinical utility in combination with current imaging techniques.”

Epigenomics’ DNA methylation biomarker panel, including the SHOX2, FOXL2 and PTGER4 genes, was compared with two proteins commonly reported as lung cancer biomarkers. Levels of DNA methylation were analyzed in two independent case-control sets of plasma samples. The training set (30 plasma samples) and the larger testing study (151 plasma samples) included all major histological types and covered a broad range of lung cancer stages (IA to IV). The DNA methylation panel displayed high sensitivity in detecting lung cancer. The findings observed in the training study were confirmed in the testing study. Test sensitivity was reported at 95% with a specificity of 64%, thus allowing its use as a confirmatory test for positively tested patients in a low dose spiral computed tomography (“LDCT”) screening.
 

About lung cancer

According to the World Health Organization, lung cancer is the leading cause of cancer death worldwide. The vast majority of cases of lung cancer are due to long-term exposure to tobacco smoke. Early detection and treatment of lung cancer can save lives: Survival rates for patients with lung cancer fall as the stage at diagnosis becomes more advanced.
 

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The Company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon(R), is a blood-based screening test for the early detection of colorectal cancer. Epi proColon(R) is currently marketed in Europe and China. For more information, visit www.epigenomics.com.
 

Contact Epigenomics AG

Peter Vogt
Investor & Public Relations
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

For U.S. press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
pr@epigenomics.com
 

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.